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Inter-embodiment and the experience of genetic testing for familial 
hypercholesterolemia 
 2 
Abstract 
In this paper, we explore the concept of inter-embodiment and its potential for 
advancing sociological research into illness biography and genetic identity.  Inter-
embodiment views embodied knowledge as produced through relations between 
bodies, as opposed to originating from within the body or as the product of relations 
between dis-embodied selves.  Drawing on our qualitative study, in which we 
interviewed 38 participants about their experiences of discovering high cholesterol 
and undergoing genetic testing for familial hypercholesterolemia (FH), we discuss 
how their narratives may be understood from an inter-embodiment perspective.  
Participants frequently talked at length about their family histories of high cholesterol 
and/or cardiovascular disease.  Through these accounts, we develop the concept of the 
family corpus in order to highlight the role body-networks play in shaping lay 
constructions of genetic identity and familial disease biography.  The family corpus, 
we argue, is useful in understanding why participants experienced genetic testing for 
FH as either biographical re-enforcement (Carricaburu and Pierret 1995) or as 
biographical disruption (Bury 1982).  We conclude by discussing the implications of 
our findings for future sociological research into illness biography and genetic 
identity. 
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Introduction 
Since the 1980s, two important bodies of work have come to take centre stage within 
the sociology of health and illness.  The first has concerned itself with exploring the 
impact which the onset of chronic illness can bring to bear on patients’ biographies 
(Lawton 2003).  Early research in this area has led to an implicit focusing on the 
body, not just as the host of disease, but as the landscape upon which illness and 
identity are experienced.  The second tradition, the sociology of the new genetics, has 
focused on exploring the socio-ethical and political implications of the rise of genetic 
medicine (Conrad and Gabe 1999).  Research in this area has sought to explore 
(amongst other things) the impact of genetic testing on selfhood and on family 
relationships.  By drawing on in-depth interviews with patients diagnosed with a 
hereditary form of hypercholesterolemia, this paper will seek to explore how inter-
embodiment - the notion that embodied knowledge is the product of relations between 
bodies - can aid research within these two traditions. 
 
Sociological research into illness biography owes its greatest intellectual debt to the 
seminal work of Bury (1982) and his notion of biographical disruption. Bury 
developed this concept in order to demonstrate how the onset of chronic illness 
(rheumatoid arthritis) fundamentally throws the individual’s sense of self, their 
relations to others and their lifecourse trajectory into question.  Whilst biographical 
disruption has become one of the most widely appropriated concepts within the 
sociology of health and illness, one of the less widely recognised contributions Bury 
makes in his early paper is to show (albeit implicitly) how biographical disruption is 
firmly located within patients’ embodied experiences of ill health.  According to 
Bury, experiences of pain and discomfort caused by the onset of rheumatoid arthritis 
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(RA) may provide the catalyst for biographical disruption, as these early symptoms 
can take over the individual; their intensification gradually compelling their 
acknowledgement, disclosure and the seeking of medical assistance.  Experiences of 
pain and impairment can lead, following Bury, to the posing of fundamental 
questions; such as, ‘Why me? Why now?’ (Bury 1982: 174).  Furthermore, the 
reorganisation of friend and family relationships (which Bury describes as ‘the 
mobilisation of resources’) can also be construed as being shaped by embodied 
experience; for example, as the result of the ‘functional limitations’ (Bury 1982: 175) 
which the chronically ill body may impose on the individual’s mobility, and as a 
result of the stigma and social embarrassment arising from impairment. 
 
Despite this implicit focus on embodied experience, attempts to explore how the 
impaired body is constructed in relation to the bodies of others, is not addressed in 
detail by Bury.  His analysis, however, does suggest that body relations play an 
important role in shaping illness biography.  Bury highlights, for example, how 
participants assumed that their predisposition to RA ‘must be inherited or carried in 
the blood’ (1982: 174) and how ‘interviews often turned on questions about familial 
transmission, both in terms of whether the condition might have been inherited and 
whether it might be passed to offspring’ (1982: 174).  Whilst subsequent studies have 
sought to explore the role of family relationships in shaping experiences of 
biographical disruption (e.g. Radley 1989; Wilson 2007) these have focused largely 
on exploring relations between selves as opposed to bodies.  Hence, the familial and 
the embodied aspects of illness biography continue to be treated as separate entities.  
The nature of the relationship that may exist between the two, therefore, is an area in 
need of further research. 
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Around a decade after the publication of Bury’s paper, sociologists began to turn their 
attention to the social dimensions of the new genetics.  These developments occurred 
principally in the wake of the Human Genome Project (Conrad and Gabe 1999).  
Since then, the impact of new genetic technologies on patients’ sense of self has been 
explored extensively, with several authors suggesting that the rise of the new genetics 
has led to new forms of biological subjectivity emerging (Kerr 2004).  Specifically, it 
has been suggested that the rise of genetic medicine has facilitated more ‘somatic’ 
(Novas and Rose 2000) and ‘inter-dependent’ (Kenen 1994) constructions of selfhood 
amongst those genetically at risk of disease.  Thus, it has been argued that genetic 
identity is characterised by a sense of embodied obligation (Howson 1998) or genetic 
responsibility towards others, where one’s own selfhood is defined in close relation to 
the selves of others (Hallowell 1999).  As Novas and Rose argue: 
 
‘Genetic identity is revealed and established only within a web of genetic 
connectedness, which is overlaid upon a web of family bonds and family 
memories, with their burden of mutual obligations and caring commitments, 
and with all the ethical dilemmas they entail.  In becoming part of a genetic 
network, the subject genetically at risk may re-think their relation to their 
current family – lovers, potential and actual spouses, children, grandchildren 
and so forth – in terms of the issues of risk and inheritance.  They may reshape 
their form of life – lifestyle, diet, leisure activities, alcohol, smoking – in these 
terms, which also reshapes their relations with those with whom they interact. 
Novas and Rose 2000: 490 
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Novas and Rose’s description of the web of genetic connectedness portrays a detailed 
and sophisticated account of the familial aspects of genetic identity.  Whilst this is the 
case, an appreciation of the ways in which genetic identity is influenced by relations 
between bodies, located within the web of genetic connectedness, remains under-
developed.  This, we argue, is due to Novas and Rose’s implicit treatment of the body 
as an independent and discrete unit of analysis.  Such an approach reflects Western 
notions of the embodied-self, as located within an individual corpus.  Selfhood, 
however, as previous empirical research has shown, may be experienced in ways 
which transcend the boundaries of individual bodies (Lawton 2000). As such, 
understanding how the relationships and inter-connectedness between bodies may 
serve in the construction of genetic identity is an area in need of further research. 
 
In this paper, we explore how the concept of inter-embodiment may advance 
sociological understandings of genetic identity.  In so doing, we also explore how 
inter-embodiment may advance contemporary approaches to illness biography. 
 
Inter-embodiment 
Our approach to inter-embodiment draws heavily on the seminal work of Merleau-
Ponty as well as the contemporary feminist writings of Weiss and Springgay.  
Merleau-Ponty rejects Cartesian mind-body dualism, arguing that consciousness, and 
therefore knowledge, is rooted in embodied existence (Crossley 1997; Priest 1998).  
The body, he argued, is ‘chiastic’ in nature and (as such) must be conceptualised as 
simultaneously sentient (capable of acquiring knowledge) and sensible (the object of 
knowledge acquisition).  As Merleau-Ponty (1968: 137) states: 
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‘… our body is a being of two leaves, from one side a thing among things and 
otherwise what sees them and touches them; we say, because it is evident, that 
it unites these two properties within itself, and its double belongingness to the 
order of “object” and to the order of the “subject” reveals to us quite 
unexpected relations between the two orders.’  
 
Merleau-Ponty’s conceptualisation of the body as simultaneously object and subject, 
is at the heart of his approach to intercorporeality. Intercorporeality refers to the 
position that an external world exists and that our embodied experiencing of it is a 
shared enterprise.  His writings on intercorporeality are, arguably, some of the most 
significant of Merleau-Ponty’s many contributions to contemporary body theory 
(Crossley 1995; 1997).  Merleau-Ponty argued that an inescapable nexus exists 
between the objective world and our subjective experiences.  He described this nexus 
as the ‘Flesh of the world’ (Merleau-Ponty 1968). The term Flesh is not intended to 
refer to physical matter but rather to an ‘element of Being’ (1968: 139) for which 
conventional philosophy has no equivalent.  It is the Flesh of the world which creates 
coherence between our objective existence and subjective experience, as it represents 
‘the coiling over of the visible upon the seeing body, of the tangible upon the touching 
body’ (Merleau-Ponty 1968: 146).  Hence, according to Merleau-Ponty, it is through 
Flesh that intercorporeal relations between bodies are made possible. 
 
Merleau-Ponty’s focus on the feeling body - as opposed to the ‘autonomous rational I’ 
(Springgay 2008: 22) - as that through which knowledge is formed is central to 
notions of inter-embodiment.  Inter-embodiment highlights that embodied knowledge 
is constructed not within bodies, but rather through Flesh; that which unifies bodies as 
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objects and subjects, and which ‘weaves relations’ between bodies (Merleau-Ponty 
1968: 260).  As such, embodied knowledge is constituted and reconstituted through 
our engagement with the bodies of others.  As Weiss (1999: 5) argues, ‘the experience 
of being embodied is not a “private affair,” but is always mediated by our continual 
interactions with other human and non-human bodies”.  Springgay (2008: 22) 
similarly argues that, ‘How we come to know ourselves and the world around us, our 
subjectivity, is performed, constructed, and mediated in relation with other beings.’  
 
By foregrounding the role of Flesh, and of ‘relationality’ (Springgay 2008), in the 
acquisition of embodied knowledge, inter-embodiment has clear potential for 
addressing the theoretical limitations inherent in contemporary approaches to illness 
biography and genetic identity.  In the remainder of this paper, therefore, we explore 
how our participants’ experiences of acquiring knowledge about their bodies as 
affected by a hereditary disorder of cholesterol metabolism (familial 
hypercholesterolemia) may be understood from this perspective. 
 
What is Familial Hypercholesterolemia (FH)? 
Familial Hypercholesterolemia (FH) is a dominantly inherited genetic condition 
which causes elevated serum cholesterol levels and affects approximately one in 
every 500 people (DeMott et al. 2008).  Individuals with FH are at significantly 
increased risk of premature death as a result of early onset cardiovascular disease 
(CVD).  FH leads to a greater than 50% risk of CVD in men by the age of 50 and at 
least 30% in women by the age of 60 (DeMott et al. 2008; Slack 1969).  The main 
bodily signs of FH are cholesterol deposits which are located on the tendons 
(xanthomas), around the eyes (corneal arcus), and on the eye lids (xanthelasmas).  A 
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clinical diagnosis of possible or definite FH is made by measuring the patient’s serum 
cholesterol levels, exploring their family history of high cholesterol and/or early onset 
CVD, and identifying tendon xanthomas on either the patient’s body or on the body of 
a first or second degree relative (Scientific Steering Committee on behalf of the 
Simon Broome Register Group 1991). 
 
Current NICE guidelines (DeMott et al. 2008) identify DNA testing as the preferred 
method of diagnosing FH.  This is because identifying a known gene mutation can 
reduce diagnostic ambiguities (Humphries et al. 2006) and aid diagnosis amongst 
relatives (Leren 2004).  Given the risks of CVD, the effectiveness of statins, and the 
fact that the majority of affected individuals are undiagnosed (Neil et al. 2000; Marks 
et al. 2004), cascade genetic screening programmes have been developed in a number 
of European countries; including the Netherlands (Umans-Eckenhausen et al. 2001), 
Spain (Pocovi et al. 2004) and Norway (Leren et al. 2004).  These programmes 
involve index patients with definite or possible FH being asked to undergo DNA 
testing and their family members contacted should a known mutation be identified.  
FH genetic cascade screening programmes have recently been introduced in the UK, 
both in Scotland (Finnie 2010) and Wales (Datta et al. 2010) and extending provision 
of DNA testing in England has recently been recommended (Pederson et al. 2010). 
 
Methods 
We conducted in-depth interviews with patients from the Lothian region of Scotland 
who took part in the nationwide FH DNA screening programme.  As part of the 
programme, patients who attended specialist lipid clinics within NHS Lothian, who 
had a diagnosis of possible or definite FH, were asked to provide blood samples for 
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the purposes of genetic testing.  If a gene mutation was identified, patients were 
referred to a genetics clinic to discuss their results and to identify at-risk relatives 
(Finnie 2010).  If a gene mutation was not identified, patients received a letter from 
the lipid clinic informing them that their results were inconclusive (as a negative 
DNA result does not rule out FH amongst index patients), and recommending that 
they encourage family members to monitor their cholesterol levels (see Hallowell, 
Jenkins et al. 2011). 
 
Patients from the screening programme were recruited using an opt-in procedure.  
One hundred and fourteen patients with DNA results - as well as the one patient listed 
on the clinical database as having formally declined genetic testing - were contacted 
between May-December 2010, either by letter or face-to-face (total n=115). Each 
patient received an information sheet outlining the study, an expression of interest 
form and a stamped addressed envelope.  Patients who wished to opt-in to the study 
were asked to complete the expression of interest form and return it to the research 
team. Of the 115 patients contacted, 43 opted-in, all of whom had consented to 
genetic testing and had received their DNA results.  Of these, 38 patients were 
interviewed.  One participant was excluded as they were outside the inclusion criteria 
and four were unavailable for interview. The majority of participants were female, 
over 45 years of age and came from educated, non-manual backgrounds (See table 1)  
 
Table 1 here 
 
A series of observations were conducted at the lipid and genetics clinics, as were in-
depth interviews with key health professionals working within them; 37 patient 
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consultations were observed and 8 health professionals interviewed.  These were 
conducted in order to gain insight into how the care of FH patients was managed; to 
explore patterns in doctor-patient interactions; and to explore how genetic testing and 
contacting family members were broached with patients.  Findings from the health 
professional interviews and clinic observations were fed into the development of the 
patient interview topic guide, and were also used to contextualise and interpret 
patients’ accounts. 
 
Patient interviews were conducted between June - December 2010.  With the 
exception of one interview that was conducted online, using instant messaging, and 
took over 4 hours, these ranged from 48 to 116 min.  Interviews explored: experiences 
of discovering high cholesterol; personal and familial disease histories, experiences of 
genetic testing; and, the impact of DNA results on disease perceptions.  The 
interviews were digitally recorded, transcribed and analysed using an inductive 
approach, with data collection and analysis running concurrently (Strauss and Corbin 
1990).  Interview transcripts were systematically compared in order to identify cross-
cutting themes and highlight common experiences.  Themes which emerged in early 
interviews were thus explored in-depth in subsequent interviews.  During data 
collection, transcripts were reviewed regularly and independently by core members of 
the research team, who met to identify common themes and discuss areas of 
agreement and divergence.  A coding framework was developed to capture data 
relating to the primary research aims as well as emergent themes.  Data collection 
ceased at the point where no new themes were identified.  NVivo 8 (Victoria, 
Australia) was used to manage the data. 
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Results 
Participants’ accounts highlighted the role of bodies-in-relation (where the status of 
the body is defined in close reference to other bodies) in the construction of 
knowledge about high cholesterol.  Whilst knowledge of family members affected by 
high cholesterol and/or CVD often prompted participants to get their own cholesterol 
levels checked, the discovery of cholesterol deposits on their own bodies prompted 
participants to re-interpret the markers visible on the bodies of their relatives.  
Participants’ understandings of the inter-connectedness of their and their family 
members’ bodies was central in their accounts of receiving DNA results.  Whilst 
positive DNA results could re-enforce participants’ sense of a familial disease 
biography and of a shared ‘family corpus’, inconclusive DNA results could result in a 
sense of biographical disruption.  This was because inconclusive results challenged 
participants’ understandings of the cause of their condition, which prompted them to 
question why they had high cholesterol. 
 
Discovering and interpreting high cholesterol: the role of bodies-in-relation 
In contrast to other chronic health conditions, hypercholesterolemia does not usually 
produce incarnate sensations (such as excessive tiredness or thirst) that may trigger an 
awareness of the disorder’s existence.  In this context, some participants specifically 
highlighted how having high cholesterol was, from their embodied point of view, 
invisible. 
 
P - Cholesterol’s a kind of hidden thing … I’m sure if you’ve got high blood 
pressure … I imagine you feel on a day-to-day basis you maybe feel lethargic 
or, I don’t know how people with high blood pressure feel.  But, you know, 
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it’s [hypercholesterolemia] not a disease that has any symptoms, or is a 
condition that has any symptoms, that it makes you feel ill or anything … 
[FH40: Male, aged 41] 
 
Given the ‘hidden’ nature of hypercholesterolemia, the most consistent factor which 
first alerted participants to their condition was not the presence of pain or dysfunction 
within their own bodies, but seeing other family members die or become seriously ill 
as a result of developing CVD.  Thus, participants’ accounts frequently highlighted 
how the premature death of a parent, grandparent or sibling had first prompted them 
to consider their own potential vulnerability to CVD and to seek medical advice. 
 
I -  ... could just tell me, just in your own words really, about how you first 
found out you had high cholesterol, how the genetic test came about, your sort 
of story, I suppose? 
P - Ok.  Well, I, my mother died when she was in her mid-fifties of coronary 
thrombosis.  I mean, it was a long time ago so cholesterol wasn’t really a big 
issue in those days … But I wondered.  I always wondered whether I had, 
whether the cholesterol was affecting me …. 
[FH16: Female, aged 65] 
 
Whilst incidences of CVD and premature death in the family often led participants to 
access cholesterol screening, experiences of attending specialist lipid clinics were 
instrumental in promoting understandings of high cholesterol as running across the 
family.  Our observations of the lipid clinics highlighted that a standard procedure 
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was followed for each new patient being seen.  The following extract from a set of 
clinic observation notes summarises the nature of these consultations: 
 
The consultations began with the doctor reviewing the patient’s 
diagnosis/disease history and the reason(s) for their referral.  This was 
followed by both open and more targeted questions about the patient’s current 
state of health and any experiences of illness symptoms.  A brief family 
history was then taken for each patient, focusing on the patient’s current 
family status (married, children etc) and on any experiences of CVD amongst 
their parents, grandparents, aunts and uncles etc.  The patient’s lifestyle was 
then discussed (including occupation, alcohol and tobacco usage, diet and 
level of physical activity) and current medications checked.  This was 
followed by a physical examination which included checking the patient’s 
pulse (at neck, waist, groin), and for any signs of xanthomas. 
(Extract from clinic observation notes: 28
th
 April, 2010) 
 
Being physically examined in the lipid clinic could result in patients developing an 
awareness of markers visible on the surfaces of their bodies (xanthomas, corneal 
arcus, xanthelasmas) as being the bodily manifestations of high cholesterol. 
 
P - When I was examined first at the lipid clinic I had a, oh, what’s it called, is 
it an xanthoma or something?  A large lump on my Achilles tendon.  Now, I 
had gone to the GP about that on several occasions and they had said, “Oh, it’s 
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just tendonitis”, because I used to do lots of hill-walking and bag munros1 and 
things.  So I was rather shocked. 
[FH31: Female, aged 60] 
 
Such re-interpretations of their own bodies led these participants to examine and re-
interpret the bodies of family members, as they made connections between the 
cholesterol markers under their own skin and the signs located on the bodies of their 
relatives. 
 
P - [The doctor] started explaining about the lumps in my fingers and the ones 
in my knees and the ones in my heels.  And that’s what he said that these are 
all linked to high cholesterol.  And I remember my mother, she had them in 
her eyes – some people have them in their eyes, they’re up here on the lid and 
they’re yellow.  I’ve never had that, right enough, but I know that that is part 
of high cholesterol as well.   
[FH38: Female, aged 61] 
 
P - I also have circles round my eyes that are a colour and my dad had that, not 
that they ever thought it was anything to do with cholesterol.  That was 
obviously what came in later on when they explained that was a sign of high 
cholesterol.  We just used to think my dad had funny eyes, you know. 
[FH35: Female, aged 52] 
 
                                                 
1
 Munros are mountains in Scotland over 3000ft and are named after Sir Hugh Munro, who first 
catalogued them.  ‘Bagging munros’ refers to the practice of climbing each of the 283 munros in 
Scotland.  
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This new understanding as to how cholesterol could manifest itself upon the surface 
of the body prompted some participants to encourage relatives, who were perceived as 
having similar body markers, to get their cholesterol checked. 
 
P - …… when I first noticed my cholesterol, I got little spots round my eyes, 
little white spots, and that’s what he’s [father] got round his eyes and I’m like 
that, “You need to go and get your cholesterol tested”. 
[FH41: Female, aged 18] 
 
P - I said to (name) to go and get tested because she had, you know how you 
get these, like, fatty blisters just at your eyes and I thought that was a, em, sort 
of symptom … 
[FH24: Female, aged 67] 
 
Interpreting the risks of having high cholesterol 
Although the extent of participants’ family histories of CVD varied, all highlighted at 
least one relative with either elevated cholesterol levels or who had died prematurely 
as a result of developing CVD.  Whilst this was the case, perceptions of risk 
associated with having high cholesterol appeared to be influenced, at least in part, by 
prior experiences of, and exposure to, affected bodies.  Some participants, for 
example, described how traumatic experiences of seeing parents suffer poor heart 
health had had a strong impact when it came to assessing the threat which having high 
cholesterol posed to them. 
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P - I suppose when I first heard I thought, Oh right.  High cholesterol, what 
does it mean?  And then when I did find out what it meant it did make me 
think, Oh God, that’s it, I’ve got a life sentence!  You know, I’m not going to 
get past sixty.  Dad never got past sixty. 
[FH05: Female, aged 47] 
 
P - I did know what it [cholesterol] was and I had heard about it and I knew 
my mum had it and I knew I had it… I probably never realised maybe how 
dangerous it was and how important it was until my mum took her heart 
attack, and I was 21 …. the first time I took it really, really serious was 
probably at my first [lipid clinic] appointment.  I was kind of a bit freaked out 
about getting an ECG and stuff like that, you know, just all the basic tests that 
they do on your first appointment.  Because I did think to myself, Oh my 
goodness, I’m only 29!  And I’d seen my mum getting ECGs and stuff like 
that with her heart problems that she had and yeah, it kind of freaked me out a 
bit. 
[FH34:  Female, aged 29] 
 
Whilst experiences of seeing family members die or suffer ill health as a result of 
developing CVD could lead participants to emphasise the vulnerability of their own 
bodies, limited exposure to CVD-related deaths in the family could also be a factor in 
participants viewing cholesterol as (personally) less-threatening. 
 
P - I suppose the link I was making in my mind then was young deaths from 
cardiovascular disease were associated with high cholesterol yet bizarrely I 
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seemed to have very high cholesterol yet did not seem to have any family 
history of early death … So I suppose I’ve received it as an intellectual risk 
but not really applying to me. 
[FH18: Male, aged 55] 
 
In short, participants’ accounts of discovering their high cholesterol and of 
interpreting the risks it presented to them highlight the role of bodies-in-relation, 
where the status of one’s own body is interpreted in close relation to the bodies of 
others.  This inter-connectedness between bodies was central to participants’ 
understandings of their DNA test results, which we discuss below. 
 
FH genetic testing: Re-enforcing and disrupting constructions of the family corpus 
As we have reported elsewhere, participants were receptive to the idea of taking part 
in genetic screening for FH.  This was because their experiences of managing their 
cholesterol over the years, the incidences of CVD in their families, and their 
interactions with health professionals had already led them to the conclusion that their 
propensity towards high cholesterol was inherited (Jenkins, Lawton et al. 2011).  As 
one participant explained: 
 
P - I guess it’s a bit of a different thing if you discover you’ve got this and 
you’ve never had a relative die of heart disease and thought you were all 
perfectly healthy but, you know, we know we’ve got that [high cholesterol] in 
our family. 
[FH12: Male, aged 54] 
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Most expected that genetic testing would confirm the link between theirs and their 
family members’ bodies.  As such, obtaining positive DNA results could provide 
participants with a sense of biographical re-enforcement (Carricaburu and Pierret 
1995).  This was because positive results established definitely for participants that 
the propensity towards high cholesterol ran across, what we term, the family corpus. 
The family corpus, as an analytical term, is employed here as a means of inter-
embodying Novas and Rose’s web of genetic connectedness described earlier (Novas 
and Rose 2000: 490).  In essence, the family corpus refers to lay perceptions of a 
shared and interdependent embodied identity that is distributed across the bodies of 
family members.  Thus, within the family corpus, each body may be understood as a 
node linked to the bodies of others by “blood lines”.  Blood lines carry the material 
through which each body-node is constructed.  As FH37 illustrates, it was through 
reference to these ties, and to the relationships between bodies in the family corpus, 
that participants interpreted positive DNA results as a form of biographical re-
enforcement: 
 
I - … having this genetic test or getting that result; has that taught you 
anything new so much or is it things which you already knew? 
P- Well, it’s just confirmed exactly what you know is probably going through 
the family.  You know, it probably is a genetic thing and, you know, if we had 
all been tested, fully tested, then we probably would know that this is going 
through the family.  And it’s not going to stop at me, you know, the blood 
line’s going to go somewhere else …  I don’t think it’s made any changes, I 
know that because it has went through the family the possibilities are that it 
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was genetic anyway.  So it’s not come as a surprise or anything like that, it’s 
something that’s there. 
 [FH37: Female, aged 53] 
 
The concept of the family corpus - as an inter-embodied network of genetic 
connectedness – also helped us to understand participants’ responses to inconclusive 
DNA results.  Whilst the major, known gene mutations associated with FH are 
routinely screened for in analysis, the detection rate can be less than 50 per cent 
(Leren 2004).  Although inconclusive DNA results do not (in themselves) rule out a 
genetic predisposition to high cholesterol, the majority of participants who had 
received inconclusive results appeared to interpret them, at least to begin with, as 
meaning that their condition was not genetic in origin.  The tendency to interpret 
inconclusive DNA results as meaning that a hereditary disorder is not genetic has 
been observed in previous research with patients who have undergone genetic testing 
in relation to breast/ovarian forms of cancer (Hallowell et al. 2002)  Interpreting 
inconclusive DNA results in this fashion could lead to experiences of biographical 
disruption.  This was because the results dis-associated participants’ bodies from 
those of their family members, as the following quote illustrates: 
 
P - … my dad was not a well man … I [don’t] remember a lot of my father but 
I do remember him coming home from the hospital having had his bypass, so I 
remember his illness and the heart disease and to that end, I was actually quite 
surprised that, well, where I was couldn’t be genetically linked to somebody or 
something else.  
[FH07: Male, aged 41] 
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Inconclusive DNA results were experienced as disruptive because they challenged 
participants’ beliefs that their own tendency towards high cholesterol could be located 
within the family corpus.  Hence, in the absence of a definitive link, participants with 
inconclusive results were often left feeling unsure as to what was causing their 
condition, as they did not consider their bodies to (otherwise) be candidates for high 
cholesterol. 
 
 I - Right.  Does that, can you say how that [DNA result] makes you feel?   
P - It still doesn’t answer the question about why you have got it; does it?  
They ruled that out, yeah fine.  You can get on with the research, yeah.  But it 
doesn’t answer my question:  Why do I have this?  As I say, I think I am pretty 
healthy, I thought I was….. When I speak to people, hardly anybody can 
believe that I have high cholesterol.  You know, as I say I’m fairly active. I’m 
not overweight.  I watch what I eat, but if I wasn’t on these statins my high 
cholesterol would be away off the scale; but why is it?  
[FH10: Male, aged 50] 
Following this participant, interpreting inconclusive results as negative could lead - in 
Bury’s terms - to the posing of key questions, such as ‘Why me? Why now?’ (Bury 
1982: 174).  In contrast to Bury’s participants, however, the posing of these questions 
did not originate from the onset of a chronic condition, but from the dissolution of an 
acceptable explanation as to its cause. 
 
Discussion 
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We began this paper by arguing that the concept of inter-embodiment can advance 
sociological research into illness biography and genetic identity.  Inter-embodiment, 
as developed by Weiss (1999) and Springgay (2008; 2010), highlights that embodied 
experiences are not ‘private affairs’ (Weiss 1999: 5) but the product of our 
interactions with the bodies of others.  As such, inter-embodiment is rooted firmly 
within a Merleau-Pontian approach to the body and within notions of flesh and of 
intercorporeality in particular.  Inter-embodiment emphasises how the material nature 
of our bodies plays a crucial role in determining relations between individuals and, 
therefore, shapes the (intercorporeal) relations through which body knowledge and 
self-identity are constructed. 
 
We have explored participants’ accounts of discovering high cholesterol and of 
undergoing genetic testing for FH from an inter-embodiment perspective.  The 
discovery, amongst participants, that their bodies contained high levels of cholesterol 
often stemmed from their knowledge of the bodies of family members, especially 
those who had died from CVD.  This knowledge prompted participants to consider 
their own vulnerability to future ill-health.  Experiences of attending lipid clinics re-
enforced understandings of high cholesterol as running across the family.  This was 
because, through their interactions with specialist doctors, participants could arrive at 
interpretations of the lumps, spots and rings on the surfaces of their bodies as being 
the bodily manifestations of high cholesterol.  These discoveries prompted 
participants to make connections between their own body markers and the lumps, 
spots and rings visible on the bodies of their relatives.  Such doctor-patient 
interactions aided the construction of a familial disease biography in which 
hypercholesterolemia was spatialized (Foucault 1973) across the bodies of the family.  
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In this context, genetic testing for FH was viewed as a means of confirming existing, 
inter-embodied understandings rather than offering new insights into participants’ 
condition.  Hence, participants who received positive DNA results tended to 
experience these as a form of biographical re-enforcement (Carricaburu and Pierret 
1995), whilst those who received inconclusive results (and who interpreted them as 
meaning that their condition was not genetic) experienced a degree of biographical 
disruption (Bury 1982).  This was because, whilst positive DNA results definitely 
located participants’ predispositions to high cholesterol as running across the bodies 
of the family, inconclusive results challenged participants’ existing assumptions that 
their bodies could be understood in relation to the bodies of their relatives. 
 
What, then, does the concept of inter-embodiment add to understandings of illness 
biography, and of genetic identity?  Because inter-embodiment emphasises that body 
knowledge and self-identity is constructed via the interaction which takes place 
between bodies, it serves to highlight that experiences of biographical disruption (or 
biographical re-enforcement) are processes in which the bodies of others play an 
integral role.  Previous authors (e.g. Hubbard 2010; Wilson 2007) have highlighted 
the need to consider the utility of biographical disruption within the various contexts 
in which illness is experienced.  Research from within the illness biography tradition 
often draws a distinction between the familial and the embodied aspects of illness 
biography, which (arguably) has little resonance when exploring experiences of 
disorders that are believed to have a hereditary cause.  In the case of genetic forms of 
disease, research has highlighted that the biographies and anticipated life trajectories 
of individuals are often intricately connected to the biographies and trajectories of 
family members (Cox and McKellin 1999; Featherstone et al. 2006).  Previous 
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research into lay understandings of coronary heart disease have highlighted how 
susceptibility to poor heart heath is often viewed as an inherited trait, and that 
experiences of witnessing family members die or become seriously ill as a result of 
developing CVD can lead individuals to consider, and to emphasise, their own 
vulnerability to the disease (Davison et al. 1989; Emslie et al. 2003; Walter et al. 
2004).  In this context, an individual’s discovery that they are affected by a genetic 
disorder which increases their risk of cardiovascular disease can provide a degree of 
biographical re-enforcement (despite its potential implications for the individuals’ 
own future health) when vulnerability to heart disease is believed to be an integral 
aspect of the wider family story. As such, and following Finkler (2000), genetic 
testing for conditions such as FH may contribute to the developing familial narrative, 
facilitating feelings of mutual connectedness and a shared (embodied) identity. 
 
In this paper, we introduce the concept of the family corpus in order to highlight how 
a shared embodied identity was drawn upon by participants in the interpretation of 
their DNA results.  The concept of the family corpus is not intended as a radical 
departure from current theorising on lay understandings of the new genetics.  Rather, 
it highlights how bodies play a crucial role in shaping what Novas and Rose describe 
as the web of genetic connectedness, within which individuals ‘re-think their relation 
to their current family … in terms of the issues of risk and inheritance’ (Novas and 
Rose 2000: 490).  As such, we hope that the concept of the family corpus may 
advance future discussion of genetic identity, of genetic responsibility, and of selves-
in-relation, by considering the role of bodies-in-relation, as well as how illness and 
self-identity may be experienced in ways that transcend individual bodies. 
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Whilst inter-embodiment may have a role to play in advancing research within the 
sociology of health and illness, it must be noted that inherited disorders, especially 
those which produce visible bodily manifestations, may be particularly amenable to 
this approach.  Clinical criteria for diagnosing FH, for example, rely heavily on the 
body status of a patient’s relatives, thereby actively promoting consideration of other 
bodies in the diagnostic process.   Weiner (2009: 415) highlights how FH patients 
frequently distinguished between their own ‘inherited cholesterol’ and the ‘ordinary 
cholesterol’ experienced by non-FH patients and which is attributed to poor diet and 
lifestyle practices.  Whilst this is the case, Weiner (2010) argues that for her 
participants at least, narratives of FH were not highly influenced by experiences of 
family members or by a shared sense of identity.  As Weiner states: 
 
‘… people’s talk about their experiences of FH does not suggest a strong sense 
of collective identity based around the condition…. many interviewees either 
did not discuss family history or talked of piecing family health histories 
together after their own diagnosis was established.’ 
Weiner 2010: 3 
 
Weiner’s finding that participants often did not discuss their family histories, or may 
not have been particularly aware of a familial propensity to CVD prior to diagnosis, is 
in stark contrast to our own findings.  As we have highlighted, the majority of 
participants reported discovering their high cholesterol as a result of their family 
histories.  Furthermore, mention of family members is a cross-cutting theme which 
runs through the interview extracts we have presented.  It is possible that differences 
between our findings are, in part, a product of differing research designs.  Our 
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participants, for example, were asked to discuss their family histories in-depth during 
the interviews, and family pedigrees were taken down by the researcher, which may 
have resulted in a more explicit focus on family members than was the case in 
Weiner’s study.  However, patients’ experiences of FH are likely to be influenced 
heavily by their interactions with health professionals (Will, Armstrong et al. 2010).  
As such, experiences of undergoing DNA testing and of attending lipid clinics which 
place a strong emphasis on exploring family histories of CVD, are likely to have 
played a pivotal role in highlighting to our participants, the significance of family 
members’ bodies.  As Table 1 highlights, approximately half of our participants came 
from professional, non-manual backgrounds.  As we have argued elsewhere (Jenkins, 
Lawton et al. 2011) this is similar to Weiner’s study and is likely due to low numbers 
of patients from manual backgrounds attending specialist lipid clinics.  All patients 
who took part in the current study had consented to genetic testing and had received 
their DNA results.  As such, it should be noted that the accounts of patients who 
decline genetic testing (or who do not attend specialist lipid clinics) could be very 
different to those presented above.  
 
The exploration of inter-embodiment from within the sociology of health and illness 
is in its infancy.  In this paper, we have demonstrated how inter-embodiment aided 
understandings of patients’ accounts of discovering high cholesterol and undergoing 
genetic testing for familial hypercholesterolemia (FH).  Other medical sociologists 
could usefully explore alternative ways of defining, and applying, the concept of 
inter-embodiment within our (sub) discipline. 
 
Acknowledgements 
 27 
We would like to thank all the patients who took part in the study, as well as the staff 
at all of the clinics that assisted us; in particular, Dr Simon Walker, Dr Bob Finnie, 
Prof Mary Porteous, Catriona Whyte, Dr Suzanne Mackenzie and Tricia Livani. We 
are grateful to Lesley Gardner, Lisa Horsburgh and Rosa Bisset whose secretarial and 
administrative skills were invaluable to the successful running of the project. The 
research was funded by a grant to Nina Hallowell, Margaret Douglas and Julia 
Lawton from the Chief Scientist’s Office.  We would also like to thank Dr Martyn 
Pickersgill, Dr Emma Rawlins, Neneh Rowar-Dewar, Dr Amy Chandler and Dr 
Catriona Rooke for their insightful and constructive comments on an earlier version of 
this paper. 
 
References 
Bury, M. (1982) Chronic illness as biographical disruption, Sociology of Health and 
Illness, 4, 2, 167-182 
 
Carricaburu, D. and Pierret, J. (1995) From biographical disruption to biographical 
reinforcement: The case of HIV-positive men, Sociology of Health and Illness, 17, 1, 
65-88 
 
Conrad, P. and Gabe, J. (1999) Introduction: Sociological perspectives on the new 
genetics: An overview, Sociology of Health and Illness, 21, 5, 505-516 
 
Cox, S. and McKellin, W. (1999) ‘There’s this thing in our family’: Predictive testing 
and the construction of risk for Huntington Disease, Sociology of Health and Illness, 
21, 5, 622–646 
 28 
 
Crossley, N. (1997) Corporeality and communicative action: Embodying the renewal 
of critical theory, Body and Society, 3, 1, 17-46 
 
Crossley, N. (1995) Body techniques, agency and intercorporeality: On Goffman’s 
relations in public, Sociology, 29, 1, 133-149 
 
Datta, B., McDowell, I. and Rees, A. (2010) Integrating provision of specialist lipid 
services with cascade testing for familial hypercholesterolaemia, Current Opinion in 
Lipidology, 21, 4, 366-371 
 
Davison, C., Frankel, S., and Davey Smith, G. (1989) Inheriting heart trouble: the 
relevance of common-sense ideas to preventative measures, Health Education 
Research, 4, 3, 329-340 
 
DeMott, K., Nherera, L., Shaw, E., Minhas, R., Humphries, S., Kathoria, M., Ritchie, 
G., Nunes, V., Davies, D., Lee, P., McDowell, I., Neil, A., Qureshi, N., Rowlands, P., 
Seed, M., Stracey, H., Thorogood, M. and Watson, M. (2008) Clinical Guidelines and 
Evidence Review for Familial Hypercholesterolaemia: The Identification and 
Management of Adults and Children with Familial Hypercholesterolaemia. London: 
National Collaborating Centre for Primary Care and Royal College of General 
Practitioners 
 
 29 
Emslie, C., Hunt, K., and Watt, G. (2003) A chip off the old block?  Lay 
understandings of inheritance among men and women in mid-life, Public 
Understanding of Science, 12, 47-65 
 
Featherstone, K., Atkinson, P., Bharadwaj, A. and Clarke, A. (2006) Risky Relations: 
Family, Kinship and the New Genetics. Oxford: Berg 
 
Finkler, K. (2000) Experiencing the New Genetics. Family and Kinship on the 
Medical Frontier. Philadelphia: University of Pennsylvania Press 
 
Finnie, R. (2010) Cascade screening for familial hypercholesterolaemia in Scotland, 
British Journal of Diabetes and Vascular Disease, 10, 3, 123-125 
 
Foucault, M. (1973) The Birth of the Clinic: An Archaeology of Medical Perception. 
London: Tavistock Publications Ltd 
 
Hallowell, N. (1999) Doing the right thing: Genetic risk and responsibility, Sociology 
of Health and Illness, 21, 5, 597-621 
 
Hallowell, N., Jenkins, N., Douglas, M., Walker, S., Finnie, R., Porteous, M. and 
Lawton, J. (2011) Patients' experiences and views of cascade screening for familial 
hypercholesterolemia (FH): a qualitative study, Journal of Community Genetics, 2, 4, 
249-257 
 
 30 
Hallowell, N., Foster, C., Ardern-Jones, A., Eeles, R., Murday, V. and Watson, M. 
(2002) Genetic testing for women previously diagnosed with breast/ovarian cancer: 
Explaining the impact of BRCA1 and BRCA2 mutation searching, Genetic Testing, 6, 
2, 79-87 
 
Howson, A. (1998) Embodied obligation: The female body and health surveillance. 
In Nettleton, S. and Watson, J. (eds) The Body in Everyday Life. London and New 
York: Routledge. pp. 218-240 
 
Hubbard, G., Kidd, L. and Kearney, N. (2010) Disrupted lives and threats to identity: 
The experiences of people with colorectal cancer within the first year following 
diagnosis, Health, 14, 2, 131-146 
 
Humphries, S., Cranston, T., Allen, M., Middleton-Price, H., Fernandez, M., Senior, 
V., Hawe, E., Iversen, A., Wray, R., Crook, M. and Wierzbicki, A. (2006) Mutational 
analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: 
Relationship with plasma lipid traits, heart disease risk and utility in relative tracing, 
Journal of Molecular Medicine, 84, 3, 203-214 
 
Jenkins, N., Lawton, J., Douglas, M., Walker, S., Finnie, R., Porteous, M. and 
Hallowell, N. (2011) How do index patients participating in genetic screening 
programmes for familial hypercholesterolemia (FH) interpret their DNA results? A 
UK-based qualitative interview study, Patient Education and Counselling, DOI: 
10.1016/j.pec.2011.09.002 
 
 31 
Kenen, R. (1994) The Human Genome Project: Creator of the potentially sick, 
potentially vulnerable and potentially stigmatized? In Robinson, I. (ed) Life and 
Death Under High Technology Medicine. Manchester: Manchester University 
Press. pp. 49-64 
 
Kerr, A. (2004) Genetics And Society: A Sociology of Disease. London and New 
York: Routledge 
 
Lawton, J. (2003) Lay experiences of health and illness: Past research and future 
agendas, Sociology of Health and Illness, 25, 3, 23-40 
 
Lawton, J. (2000) The Dying Process: Patients’ Experiences of Palliative Care. 
London and New York: Routledge 
 
Leren, T. (2004) Cascade genetic screening for familial hypercholesterolemia, 
Clinical Genetics, 66, 6, 483-487 
 
Leren, T., Manshaus, T., Skovholt, U., Skodje, T., Nossen, I., Teie, C., Sørensen, S. 
and Bakken, K. (2004) Application of molecular genetics for diagnosing familial 
hypercholesterolemia in Norway: Results from a family-based screening program, 
Seminars in Vascular Medicine, 4, 1, 75-85 
 
Marks, D., Thorogood, M., Farrer, J. and Humphries, S. (2004) Census of clinics 
providing specialist lipid services in the United Kingdom, Journal of Public Health, 
26, 4, 353-354 
 32 
 
Merleau-Ponty, M. (1968) The Visible and the Invisible: Followed by Working Notes. 
Evanston:  Northwestern University Press 
 
Neil, H., Hammond, T., Huxley, R., Matthews, D. and Humphries, S. (2000) Extent of 
underdiagnosis of familial hypercholesterolaemia in routine practice: Prospective 
registry study, British Medical Journal, 321, 7254, 148 
 
Novas, C. and Rose, N. (2000) Genetic risk and the birth of the somatic individual, 
Economy and Society, 29, 4, 485-513 
 
Pedersen, K., Humphries, S., Roughton, M. and Besford, J. (2010) National Clinical 
Audit of the Management of Familial Hypercholesterolaemia 2010: Full Report. 
Clinical Standards Department: Royal College of Physicians 
 
Pocovi, M., Civeira, F., Alonso, R. and Mata, P. (2004) Familial 
hypercholesterolemia in Spain: Case-finding program, clinical and genetic aspects, 
Seminars in Vascular Medicine, 4, 1, 67-74 
 
Priest, S. (1998) Merleau-Ponty. London and New York: Routledge 
 
Radley, A. (1989) Style, discourse and constraint in adjustment to chronic illness, 
Sociology of Health and Illness, 11, 3, 230- 252 
 
 33 
Scientific Steering Committee on behalf of the Simon Broome Register Group. (1991) 
Risk of fatal coronary heart disease in familial hypercholesterolaemia, British Medical 
Journal, 303, 6807, 893-896 
 
Slack, J. (1969) Risks of ischaemic heart-disease in familial hyperlipoproteinaemic 
states, Lancet, 2, 7635, 1380-1382 
 
Springgay, S. (2008) Body Knowledge and Curriculum: Pedagogies of Touch in 
Youth and Visual Culture. New York: Peter Lang 
 
Strauss, A. and Corbin, J. (1990) Basics of Qualitative Research: Grounded Theory 
Procedures and Techniques. London: Sage 
 
Umans-Eckenhausen, M., Defesche, J., Sijbrands, E., Scheerder, R. and Kastelein, J. 
(2001) Review of first 5 years of screening for familial hypercholesterolaemia in the 
Netherlands, Lancet, 357, 9251, 165-168 
 
Walter, F., Emery, J., Braithwaite, D., and Marteau, T. (2004) Lay understanding of 
familial risk of common chronic diseases: A systematic review and synthesis of 
qualitative research, Annals of Family Medicine, 2, 6, 583-594 
 
Weiner, K. (2010) Exploring genetic responsibility for the self, family and kin in the 
case of hereditary raised cholesterol, Social Science and Medicine, 
doi:10.1016/j.socscimed.2010.03.053 
 
 34 
Weiner, K. (2009) The tenacity of the coronary candidate: How people with familial 
hypercholesterolaemia construct raised cholesterol and coronary heart disease, Health, 
13, 4, 407-427 
 
Weiss, G. (1999) Body Images: Embodiment as Intercorporeality. London and New 
York: Routledge 
 
Will, C., Armstrong, D. and Marteau, T. (2010) Genetic unexceptionalism: Clinician 
accounts of genetic testing for familial hypercholesterolaemia, Social Science and 
Medicine, 71, 5, 910-917 
 
Wilson, S. (2007) ‘When you have children, you’re obliged to live’: Motherhood, 
chronic illness and biographical disruption. Sociology of Health and Illness, 29, 4, 
610-626 
 35 
Table 1: Participant characteristics 
 
 N 
i. Age (yrs) at interview   
Mean 52.63 
Youngest participant 18 
Eldest participant 67 
45 years  (%) 8 (21) 
  
ii. Gender (%)  
Female 21 (55) 
Male 17 (45) 
  
iii.  Education (%)  
Compulsory education 14(37) 
Further education 4(11) 
Higher – HNC/HND 4(11) 
Higher – Degree/Postgraduate 16(42) 
  
iv. Current/most recent [main] occupation (%)  
Professional and Managerial 11(29) 
Skilled non-manual 9(24) 
Semi-skilled non-manual 11(29) 
Skilled manual 2(5) 
Semi-skilled manual 1(3) 
 36 
Routine manual 2(5) 
Other/unclassified 2(5) 
  
v. Mutation status (%)  
Mutation identified 23 (61) 
No mutation identified 15 (39) 
  
vi. Clinical genetics  
Attended genetic counselling 15 (39) 
  
vii. Estimated years attending specialist lipid clinics (%)  
0-2 11 (29) 
3-4 7 (18) 
5 -9 7 (18) 
10+ 13 (34) 
Notes 
Figures principally based on patient self-report data 
Percentages are to the nearest whole number 
 
